My primary clinical and research focus is in advancing the care of patients with myeloproliferative neoplasms (MPN). My primary clinical objective is to continue to develop a panel of patients with MPN from local and regional referrals. The goal of my research is to design and implement clinical trials for patients with MPNs with a significant translational component through collaborations with laboratory investigators.
In August of 2014 I joined the Leukemia Service at Massachusetts General Hospital where I have established a MPN clinical and research program. From a clinical perspective, I routinely receive referrals from across the northeast and have a strong referral network; this has allowed me to develop a panel that consists primarily of MPN patients. From a research perspective, I lead the MPN clinical trials at MGH, all of which include a strong translational component based. The investigator-initiated studies for which I am the principal investigator include- A phase II, multicenter study, of ruxolitinib before, during and after transplant for patients with myelofibrosis (Protocol 17-569). A phase I study of Regorafenib for patients with advanced myeloid neoplasms (Protocol 16-464). A phase II, multicenter study utilizing ruxolitinib for maintenance after transplant for older patients with AML (Protocol 17-273). A phase II, multicenter study investigating the use of pembrolizumab for myelofibrosis (Protocol 17-480). In addition, I am the site PI for all pharmaceutical sponsored studies in MPN at MGH.
In addition to clinical trials work, I collaborate with Dr. Ann Mullally in translational research utilizing samples from the above-mentioned trials. This work includes defining the role of genetic mutations in predicting post- allogeneic hematopoietic stem cell transplantation (SCT) outcomes in myelofibrosis patients utilizing samples from protocol 17-569. In addition, we are investigating the role of immune dysregulation and immunotherapy in patients with MPN. This research utilizes samples of patients collected from my clinic as well as samples from a clinical trial utilizing the checkpoint inhibitor, Pembrolizumab in patients with Myelofibrosis.
Ultimately, my goal is to continue to grow a multidisciplinary MPN research program focused on providing high quality care to patients with MPNs, and to develop new treatment options for patients with MPN based on sound pre-clinical rationale, while strengthening collaborations with investigators across the Dana Farber Harvard Cancer Center and across the country.